NUNN JASON RALEIGH purchased 387.2% of their position (882.35K shares) of ZENAS BIOPHARMA, INC. on the open market
Open‑market purchase worth $15.00M — a major conviction buy. The strongest form of insider conviction signal.
Common Stock
Shares
+1.51M
Price / share
—
Trade value
—
% of position
Common Stock
Shares
+441.18K
Price / share
$17.00
Trade value
$7.50M
% of position
Common Stock
Shares
+669.06K
Price / share
—
Trade value
—
% of position
Common Stock
Shares
+441.18K
Price / share
$17.00
Trade value
$7.50M
% of position
Net shares
+3.06M
Net value
$15M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 9/16/2024 | C · Conversion | +1.51M | — | — | New position | 0.00 | 1.51M |
| Common Stock Indirect | 9/16/2024 | P · Purchase | +441.18K | $17.00 | $7.50M | 29.3% | 1.51M | 1.95M |
| Common Stock Indirect | 9/16/2024 | C · Conversion | +669.06K | — | — | New position | 0.00 | 669.06K |
| Common Stock Indirect | 9/16/2024 | P · Purchase | +441.18K | $17.00 | $7.50M | 65.9% | 669.06K | 1.11M |
| Total | +3.06M | $15M | ||||||
Stock Option (Right to Buy)
Common Stock
37K shares
Shares
+37K
Strike price
17
Held after
37K
Exercisable
—
Series C Convertible Preferred Stock
Common Stock
1.51M shares
Shares
−13.07M
Strike price
Held after
0.00
Exercisable
—
Series C Convertible Preferred Stock
Common Stock
669.06K shares
Shares
−5.81M
Strike price
Held after
0.00
Exercisable
—
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock37K shares | 9/12/2024 | A · Award | +37K | 17 | — | 37K |
| Series C Convertible Preferred Stock Indirect | Common Stock1.51M shares | 9/16/2024 | C · Conversion | −13.07M | — | 0.00 | |
| Series C Convertible Preferred Stock Indirect | Common Stock669.06K shares | 9/16/2024 | C · Conversion | −5.81M | — | 0.00 |